The DOI matches its Crossref record; 32 of the 32 references it cites were found in a registry or an index; 7 of the 44 sources its claims cite were checked for support.
Garsorasib, a KRAS G12C inhibitor, with or without cetuximab, an EGFR antibody, in colorectal cancer cohorts of a phase II trial in advanced solid tumors with KRAS G12C mutation
Open accessAbstract
Mutations in the KRAS gene have long been implicated in the pathogenesis of colorectal cancer (CRC). KRAS G12C inhibitors overcome the “undruggable” challenge, enabling precision therapy. Garsorasib (D-1553), a highly potent and selective KRAS G12C inhibitor, has demonstrated promising anti-tumor activity and favorable safety profile in early clinical trials. We conducted an open-label, nonrandomized phase II trial (ClinicalTrials.gov, NCT04585035) to assess the safety and efficacy of garsorasib with or without cetuximab in KRAS G12C-mutated CRC. In the monotherapy cohort (n = 26), objective response rate (ORR) was 19.2% (95% CI, 6.6–39.4), disease control rate (DCR) was 92.3% (95% CI, 74.9–99.1), median progression-free survival (PFS) was 5.5 months (95% CI, 2.9–11.6) and median overall survival (OS) was 13.1 months (95% CI, 9.5-NE). In the combination cohort (n = 42), ORR was 45.2% (95% CI, 29.8–61.3), DCR was 92.9% (95% CI, 80.5–98.5), median PFS was 7.5 months (95% CI, 5.5–8.1), and median OS was not reached. Grade ≥3 treatment-related adverse events occurred in 5 (19.2%) and 6 (14.3%) patients in monotherapy and combination cohort, respectively. Garsorasib with or without cetuximab showed a promising efficacy and manageable safety profiles in heavily pretreated patients with KRAS G12C-mutated CRC, providing a potential new treatment approach for such population.
Overview
CoChat Summary
TL;DR
In pretreated KRAS G12C-mutated metastatic colorectal cancer, garsorasib plus cetuximab produced higher response rates and longer progression-free survival than garsorasib monotherapy, with manageable toxicity in both cohorts. The trial was open-label and nonrandomized, so the combination’s apparent advantage requires confirmation in larger randomized studies.
Key findings
- In the monotherapy cohort (n = 26), confirmed ORR was 19.2% (95% CI, 6.6–39.4), DCR was 92.3% (95% CI, 74.9–99.1), median PFS was 5.5 months (95% CI, 2.9–11.6), and median OS was 13.1 months (95% CI, 9.5–NE).
- In the combination cohort (n = 42), confirmed ORR was 45.2% (95% CI, 29.8–61.3), DCR was 92.9% (95% CI, 80.5–98.5), median PFS was 7.5 months (95% CI, 5.5–8.1), and median OS was not reached (95% CI, 11.3–NE).
- Grade ≥3 treatment-related adverse events occurred in 5 (19.2%) patients with monotherapy and 6 (14.3%) patients with combination therapy; no fatal TRAEs were reported.
- The most common TRAEs in the combination cohort were skin/subcutaneous tissue disorders and liver function abnormalities, while monotherapy TRAEs were most commonly liver function abnormalities and gastrointestinal events.
Methods
- Open-label, nonrandomized phase II study within a multicenter phase I/II trial (NCT04585035); CRC cohorts included patients with pretreated advanced or metastatic KRAS G12C-mutated CRC.
- Monotherapy cohort: 26 patients from Arm B received oral garsorasib 600 mg twice daily. Combination cohort: 42 patients from Arm F received garsorasib 600 mg twice daily plus intravenous cetuximab 400 mg/m² on day 1 of cycle 1 and 250 mg/m² weekly thereafter.
- Primary endpoint was ORR by investigator per RECIST v1.1; secondary endpoints included DCR, PFS, DOR, OS, and adverse events. Efficacy analyses followed the ITT principle; ORR/DCR used Clopper-Pearson 95% CIs, and PFS/OS/DOR used Kaplan-Meier methods.
Limitations
- The paper states the nonrandomized design does not allow direct comparisons between garsorasib monotherapy/combination and standard-of-care.
- The paper states the sample size was relatively small and randomized trials with larger sample sizes are needed.
- The paper states follow-up was not long enough to capture the long-term survival benefit of the combination cohort; the text also notes no formal statistical hypothesis was prespecified.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures



Verification
Claims the paper makes
4 Valid · 1 Not valid · 25 Not checked · 75 Own results and interpretations
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“This specific mutation, present in ~3% of CRC cases, 2 is associated with significantly reduced progression-free survival (PFS) and overall survival (OS) compared to KRAS wildtype tumors.[3][4][5]”
§ Garsorasib, a KRAS G12C inhibitor, with or without cetuximab, an EGFR antibody, in colorectal cancer cohorts of a phase II trial in advanced solid tumors with KRAS G12C mutation > INTRODUCTION
What the sources say
- Partly supportedcites [2] Prior, I. A., Lewis, P. D. & Mattos, C. A comprehensive survey of Ras mutations in cancer. Cancer Res. 72, 2457–2467 (2012). sourceExperimental — accuracy not yet measured
The Ras mutation etiology section (page unavailable) says G12C occurs in colorectal cancer and is far less abundant there than in lung cancer. It does not give a colorectal cancer frequency of approximately 3%, so the numerical part of the claim is not supported by our copy. (LLM, conf=0.83)
hedged- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Accordingly, preclinical and clinical evidence suggests that dual targeting of KRAS G12C and EGFR could overcome this resistance mechanism.14”
§ Garsorasib, a KRAS G12C inhibitor, with or without cetuximab, an EGFR antibody, in colorectal cancer cohorts of a phase II trial in advanced solid tumors with KRAS G12C mutation > INTRODUCTION
What the sources say
- Partly supportedcites [14] Amodio, V. et al. EGFR blockade reverts resistance to KRAS(G12C) inhibition in colorectal cancer. Cancer Discov. 10, 1129–1139 (2020). sourceExperimental — accuracy not yet measured
The Introduction (p. 4) reports that combined KRAS G12C and EGFR blockade overcame adaptive resistance in CRC cell lines and patient-derived models. The clinical evidence discussed in the Introduction (p. 3) concerns limited responses to KRAS G12C inhibitors alone in CRC; the paper does not report clinical evidence that the dual treatment overcomes resistance in patients. (LLM, conf=0.88)
hedgedstates a possible cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“In terms of gastrointestinal adverse effects frequently observed in other KRAS G12C inhibitors, 11,12,28 the incidence was generally lower in garsorasib (diarrhea at 11.5%, nausea at 7.7%, and no vomiting reported), compared to those reported of other KRAS G12C inhibitors (diarrhea at 31.7-69%, nausea at 19-78%, and vomiting at 7.9-58%).”
§ Garsorasib, a KRAS G12C inhibitor, with or without cetuximab, an EGFR antibody, in colorectal cancer cohorts of a phase II trial in advanced solid tumors with KRAS G12C mutation > DISCUSSION
What the sources say
- Supportedcites [11] Yaeger, R. et al. Adagrasib with or without cetuximab in colorectal cancer with mutated KRAS G12C. N. Engl. J. Med. 388, 44–54 (2023). source
The citation is offered for the part of the sentence about gastrointestinal adverse effects 'frequently observed in other KRAS G12C inhibitors', and our copy of Yaeger et al. (adagrasib ± cetuximab, KRYSTAL-1) reports exactly that: in the Safety section (Results), treatment-related diarrhea 66%, nausea 57% and vomiting 45% in the 44-patient adagrasib monotherapy cohort, and nausea 62%, diarrhea 56%, vomiting 53% in the 32-patient adagrasib-plus-cetuximab cohort — all values falling inside the ranges the citing sentence attributes to other KRAS G12C inhibitors (diarrhea 31.7-69%, nausea 19-78%, vomiting 7.9-58%). The paper does not mention garsorasib, and the 'generally lower' comparison is the citing authors' own synthesis rather than something attributed to this source. As an exemplifying citation for adagrasib's GI toxicity profile, this source is that thing. (LLM, conf=0.85)
- Supportedcites [12] Sacher, A. et al. Single-agent divarasib (GDC-6036) in solid tumors with a KRAS G12C mutation. N. Engl. J. Med. 389, 710–721 (2023). source
Our copy of Sacher et al. (divarasib/GDC-6036, a KRAS G12C inhibitor) reports in the Safety section and Table 2 (NSCLC section) treatment-related nausea 74% overall (78% in both NSCLC and colorectal cohorts), diarrhea 61% overall (69% in colorectal cancer) and vomiting 58% — i.e. exactly the upper-bound values (69%, 78%, 58%) that the citing sentence assigns to 'other KRAS G12C inhibitors'. The Discussion likewise frames divarasib as one of the multiple KRAS G12C inhibitors with its own safety profile, so the paper validly serves as an identified source of GI adverse-effect incidence for a comparator KRAS G12C inhibitor. The garsorasib figures (11.5%, 7.7%, no vomiting) and the 'generally lower' comparison are the citing authors' own, not attributed to this source. (LLM, conf=0.85)
- Partly supportedcites [28] Skoulidis, F. et al. Sotorasib for lung cancers with KRAS p.G12C mutation. N. Engl. J. Med. 384, 2371–2381 (2021). sourceExperimental — accuracy not yet measured
Our copy of Skoulidis et al. (Results > Safety) supports the sotorasib comparator figures for diarrhea and nausea: treatment-related diarrhea in 40 patients (31.7%) and nausea in 24 (19.0%), matching the lower bounds of the cited ranges (any-grade, regardless of attribution, values were 50.8% and 31.0%). However, the paper reports no vomiting incidence at all — searched 'vomiting' and the gastrointestinal adverse-event passages, and the only 7.9% values in our copy are diarrhea and AST increase leading to dose modification — so the 'vomiting 7.9%' component attributed to this source is not supported by it. The upper bounds (diarrhea 69%, nausea 78%, vomiting 58%) belong to the other cited trials, not this paper, and the garsorasib-side numbers are the citing authors' own data. (LLM, conf=0.78)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources that could be checked couldn’t confirm or dispute this claim.
In the paper
“TRAEs of grade 3-4 occurred in 34.1% (15/44) of patients who received adagrasib monotherapy, whereas they declined to 15.6% (5/32) in patients who received adagrasib plus cetuximab.”
§ Garsorasib, a KRAS G12C inhibitor, with or without cetuximab, an EGFR antibody, in colorectal cancer cohorts of a phase II trial in advanced solid tumors with KRAS G12C mutation > DISCUSSION
What the sources say
- Could not verifycites [21] Kondo, S. et al. 1622P D-1553 in patients with KRAS G12C mutated advanced pancreatic cancer (PCA). Ann. Oncol. 34, S898–S899 (2023). sourceExperimental — accuracy not yet measured
The indexed Results passage (Abstract; page unavailable) reports grade 3 treatment-related adverse events in 2 of 10 patients treated with D-1553 for advanced pancreatic cancer. Searches for KRYSTAL-1, adagrasib, cetuximab, and the claimed patient counts found no passage addressing the adagrasib comparison or its adverse-event rates. (LLM, conf=0.77)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Could not verify
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Treatment-related adverse events (TRAEs) of any grade were reported in 14 (53.8%)patients in the monotherapy cohort”
§ Garsorasib, a KRAS G12C inhibitor, with or without cetuximab, an EGFR antibody, in colorectal cancer cohorts of a phase II trial in advanced solid tumors with KRAS G12C mutation > Safety
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
64 more claims
Create a free account to see all 105 claims and to verify the 37 references still open.
- It may state two separate claims as one. 25
- The quote only partly states this claim. 4
- Probably not a substantial claim. 9
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
“| Progressive disease | 2 (7.1) | 2 (4.8) |”
§ Garsorasib, a KRAS G12C inhibitor, with or without cetuximab, an EGFR antibody, in colorectal cancer cohorts of a phase II trial in advanced solid tumors with KRAS G12C mutation > Statistical analysis
Reported 7.1 · recomputed 7.692308
Citations
Cites
Sung, H., Ferlay, J., Siegel, R. L., Laversanne, M., Soerjomataram, I., Jemal, A., & Bray, F. (2021) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21660 · Cited by 108,699
Grothey, A., Cutsem, E. V., Sobrero, A., Siena, S., Falcone, A., Ychou, M., Humblet, Y., Bouché, O., Mineur, L., Barone, C., et al. (2013) · The Lancet · doi:10.1016/s0140-6736(12)61900-x · Cited by 2,895 · cited 1×
“30,31 Similar results were observed in other studies investigating KRAS G12C inhibitors, such as adagrasib, 16 sotorasib, 11 and divarasib, 32 as monotherapy and combination therapy.”
K-Ras(G12C) inhibitors allosterically control GTP affinity and effector interactions
Ostrem, J. M., Peters, U., Sos, M. L., Wells, J. A., & Shokat, K. M. (2013) · Nature · doi:10.1038/nature12796 · Cited by 2,557
A Comprehensive Survey of Ras Mutations in Cancer
Prior, I. A., Lewis, P. D., & Mattos, C. (2012) · Cancer Research · doi:10.1158/0008-5472.can-11-2612 · Cited by 2,063
Sotorasib for Lung Cancers with KRAS p.G12C Mutation
Skoulidis, F., Li, B. T., Dy, G. K., Price, T. J., Falchook, G. S., Wolf, J., Italiano, A., Schuler, M., Borghaei, H., Barlesi, F., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2103695 · Cited by 1,849
Randomized Trial of TAS-102 for Refractory Metastatic Colorectal Cancer
Mayer, R. J., Van Cutsem, E., Falcone, A., Yoshino, T., Garcia-Carbonero, R., Mizunuma, N., Yamazaki, K., Shimada, Y., Tabernero, J., Komatsu, Y., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1414325 · Cited by 1,431
Adagrasib with or without Cetuximab in Colorectal Cancer with Mutated KRAS G12C
Yaeger, R., Weiss, J., Pelster, M. S., Spira, A. I., Barve, M., Ou, S.-H. I., Leal, T. A., Bekaii-Saab, T. S., Paweletz, C. P., Heavey, G. A., et al. (2023) · New England Journal of Medicine · doi:10.1056/nejmoa2212419 · Cited by 527 · cited 2×
“30,31 Similar results were observed in other studies investigating KRAS G12C inhibitors, such as adagrasib, 16 sotorasib, 11 and divarasib, 32 as monotherapy and combination therapy.”
InfluentialEGFR Blockade Reverts Resistance to KRASG12C Inhibition in Colorectal Cancer.
Amodio, V., Yaeger, R., Arcella, P., Cancelliere, C., Lamba, S., Lorenzato, A., Arena, S., Montone, M., Mussolin, B., Bian, Y., et al. (2020) · Cancer Discovery · doi:10.1158/2159-8290.cd-20-0187 · Cited by 504
Sotorasib plus Panitumumab in Refractory Colorectal Cancer with Mutated KRAS G12C
Fakih, M. G., Salvatore, L., Esaki, T., Modest, D. P., Lopez-Bravo, D. P., Taieb, J., Karamouzis, M. V., Ruiz-Garcia, E., Kim, T.-W., Kuboki, Y., et al. (2023) · New England Journal of Medicine · doi:10.1056/nejmoa2308795 · Cited by 398 · cited 2×
“16 Based on these fi ndings, FDA granted accelerated approval to adagrasib plus cetuximab on June 21, 2024, and approval to sotorasib plus panitumumab on January 16, 2025.”
Modest, D. P., Ricard, I., Heinemann, V., Hegewisch-Becker, S., Schmiegel, W., Porschen, R., Stintzing, S., Graeven, U., Arnold, D., von Weikersthal, L. F., et al. (2016) · Annals of Oncology · doi:10.1093/annonc/mdw261 · Cited by 351
Cited by
Kano, Y. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27135796
Metadata
- Authors
- Ruan, D.-Y., Wu, H.-X., Xu, Y., Munster, P. N., Deng, Y., Richardson, G., Yan, D., Lee, M.-A., Lee, K.-W., Pan, H., Hager, S., Li, X., Wei, S., Hou, X., Underhill, C., Millward, M., Nordman, I., Zhang, J., Shan, J., Han, G., Grewal, J., Gadgeel, S. M., Sanborn, R. E., Huh, S. J., Hu, X., Zhang, Y., Xiang, Z., Luo, L., Xie, X., Shi, Z., Wang, Y., Zhang, L., Wang, F., & Xu, R.-H.
- Affiliations
- Sun Yat-sen University (CN)
- Fudan University (CN)
- Cabrini Hospital (AU)
- The Catholic University of Korea Seoul St. Mary's Hospital (KR)
- Seoul National University (KR)
- Sir Run Run Shaw Hospital (CN)
- California Cancer Associates for Research and Excellence (US)
- First Affiliated Hospital of Zhengzhou University (CN)
- Hubei Cancer Hospital (CN)
- Henan Cancer Hospital (CN)
- Albury Wodonga Health (AU)
- The University of Western Australia (AU)
- Calvary Mater Newcastle Hospital (AU)
- Liaoning Cancer Hospital & Institute (CN)
- First Affiliated Hospital Zhejiang University (CN)
- Henry Ford Health (US)
- Dong-A University Hospital (KR)
- First Affiliated Hospital of GuangXi Medical University (CN)
- InventisBio Co., Ltd. (China) (CN)
- Corresponding author
- Wang, Feng
- Xu, Rui-Hua
- ORCID
- Venue
- Signal Transduction and Targeted Therapy
- Published
- 2025-06-17
- Volume
- 10
- Issue
- 1
- Pages
- 189-189
- ISSN
- 2059-3635 (ISSN-L)
- OpenAlex
- W4411331277
- Semantic Scholar
- 9b33c2126a056b77780c83ed2463b6a2346e7dbb
- Cited by
- 22
- References
- 32
- Citations by year
- 2026: 16 · 2025: 6
- FWCI
- 9.11
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by
- creativecommons.org/licenses/by/4.0 (tdm)
- creativecommons.org/licenses/by/4.0 (vor)
- Locations
- Signal Transduction and Targeted Therapy (publishedVersion, cc-by)
- PubMed (publishedVersion)
- UWA Profiles and Research Repository (UWA) (submittedVersion, cc-by)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Topics
- Health Sciences › Medicine › Oncology › Colorectal Cancer Treatments and Studies
- Health Sciences › Medicine › Oncology › Colorectal Cancer Surgical Treatments
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
- Keywords
- KRAS G12C inhibitors, cetuximab, anti-EGFR monoclonal antibody, colorectal cancer, KRAS G12C mutation, combination therapy, monotherapy, advanced solid tumors, treatment-related adverse events, progression-free survival, objective response rate
- MeSH terms
- Cetuximab, Adult, Aged, Aged, 80 and over, Antineoplastic Combined Chemotherapy Protocols, Female, Humans, Male, Middle Aged, Mutation, Colorectal Neoplasms, Proto-Oncogene Proteins p21(ras), ErbB Receptors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-06, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-06 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol and qwen3.8-omni-flash).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Garsorasib, a KRAS G12C inhibitor, with or without cetuximab, an EGFR antibody, in colorectal cancer cohorts of a phase II trial in advanced solid tumors with KRAS G12C mutation. https://app.cochat.ai/papers/10.1038/s41392-025-02274-z
- The paper
- Ruan, D.-Y., Wu, H.-X., Xu, Y., Munster, P. N., Deng, Y., Richardson, G., Yan, D., Lee, M.-A., Lee, K.-W., Pan, H., Hager, S., Li, X., Wei, S., Hou, X., Underhill, C., Millward, M., Nordman, I., Zhang, J., Shan, J., . . . Xu, R.-H. (2025). Garsorasib, a KRAS G12C inhibitor, with or without cetuximab, an EGFR antibody, in colorectal cancer cohorts of a phase II trial in advanced solid tumors with KRAS G12C mutation. Signal Transduction and Targeted Therapy. https://doi.org/10.1038/s41392-025-02274-z
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.